10 Apr. 2019
BIOVERSYS AND INSTITUT PASTEUR DE LILLE WORKING TOGETHER
BioVersys AG s’implante à Lille pour intensifier la recherche et le développement de nouveaux hashtag#antibiotiques afin de combattre la résistance ba...
10 Apr. 2019
BASELAREA.SWISS EVENT ON APRIL 26TH, 2018
The BaselArea.swiss event connected key players in antibiotic-research to discuss present roadblocks to understanding antibiotic action, discovery and...
10 Apr. 2019
EMA PROPOSAL FOR IMPROVED GUIDELINES FOR TREATING BACTERIAL INFECTIONS
Marc Gitzinger speaks on behalf of the BEAM Alliance with regards to the proposal of the European Medicines to updates its two existing guidelines on...
10 Apr. 2019
DUKE MARGOLIS CENTER FOR HEALTH POLICY, WASHINGTON DC
Marc Gitzinger, representing the BEAM Alliance, was one of the invited speakers at the Duke Margolis Center: Understanding the Development Challenges...
Recent Media Feeds
- Press Release - BioVersys hires new CDO, Dr. Glenn Dale
- Eurostars Funds IMPACT2 Press Release
- Dr. Gitzinger will be speaking at the UNCTAD/WHO event in Geneva, October 23rd, 2018 from 14:30-17:30 on Fostering investment in the development of new antibacterial treatments
- CARB-X welcomes UK Government and Bill & Melinda Gates Foundation as new partners
- BioVersys successfully closes Series A2 financing round
- October 20th, 2017; BioVersys and Marc Gitzinger were featured in the 3Sat news.
- BEAM Alliance fordert G20 Staaten zu mehr Unterstützung im Kampf gegen tödliche Superkeime auf
- Swiss biopharma BioVersys is collaborating with drug discovery and development CRO Aptuit on the discovery and development of new targets and drug candidates against Gram-negative bacteria, including drug-resistant strains. An existing BioVersys target will be included in the partnership.
- Press Release BEAM Alliance / Biocom AG
- Breaking through the Wall ... A Call for Concerted Action on AB Research and Development
